Form 4: Cullinan Therapeutics' Chief Medical Officer, Jeffrey Alan Jones, Reports Stock and Option Awards

Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, reports the acquisition of 65,000 shares of common stock and options to purchase 130,000 shares.

Summary

• Jeffrey Alan Jones, the Chief Medical Officer of Cullinan Therapeutics, Inc., filed a Form 4 on February 21, 2025.
• The report details changes in his beneficial ownership of the company's securities.
• On February 19, 2025, Jones acquired 65,000 shares of common stock and options to purchase 130,000 shares.
• The shares underlying the restricted stock unit vest on an annual basis over four years.
• The options vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
• Following these transactions, Jones directly owns 179,059 shares of common stock and options for 130,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants. While insider ownership is generally viewed positively, this is a routine disclosure.

Positives

• The acquisition of stock and options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive compensation and ownership.

Key Dates

Keywords

Form 4, Cullinan Therapeutics, CGEM, Jeffrey Alan Jones, Chief Medical Officer, Stock Options, Beneficial Ownership, Securities